GlassScriptDilumen Endolumenal Interventional Platform, 103 Cm
Payments companies reported to CMS as associated with Dilumen Endolumenal Interventional Platform, 103 Cm. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Dilumen Endolumenal Interventional Platform, 103 Cm, per program year, as reported to CMS.
Who makes it
- Lumendi LLC $158K associated with Dilumen Endolumenal Interventional Platform, 103 Cm (2023-2025)
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Dilumen Endolumenal Interventional Platform, 103 Cm
These are the largest totals companies reported as associated with Dilumen Endolumenal Interventional Platform, 103 Cm. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sergey Kantsevoy | Baltimore, MD | Gastroenterology (Internal Medicine) | $57,077.62 |
| Ihya Gorgun | Cleveland, OH | Surgery | $56,395.50 |
| Molham Abdulsamad | Port Matilda, PA | Gastroenterology (Internal Medicine) | $8,186.09 |
| Ovunc Bardakcioglu | Las Vegas, NV | Surgery | $5,812.31 |
| Alexander Schlachterman | Philadelphia, PA | Gastroenterology (Internal Medicine) | $5,740.47 |
| Salmaan Jawaid | Houston, TX | Gastroenterology (Internal Medicine) | $4,867.50 |
| Venkata Muddana | Cincinnati, OH | Gastroenterology (Internal Medicine) | $4,768.49 |
| Stavros Stavropoulos | Bellmore, NY | Gastroenterology (Internal Medicine) | $4,539.07 |
| Ahmed Saeed | Kansas City, MO | Gastroenterology (Internal Medicine) | $3,200.00 |
| Mohamed Othman | Houston, TX | Gastroenterology (Internal Medicine) | $3,200.00 |
Prescribed Dilumen Endolumenal Interventional Platform, 103 Cm?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.